Abstract
We compared two groups of patients with cognitive deterioration secondary to Alzheimer's disease (AD) of minimal and slight degree (CAMDEX criteria), one treated with donepezil and the other without this drug (a case history sample) over a period of six months. Both groups received the CAMCOG battery of neuropsychological tests at basal (pretreatment) time and six months later. Those in the study sample who received donepezil (5-10 mg/day) were 91 patients (average age: 75.25, standard deviation = 6.01) of whom 28.6% were men. The control group, who did not receive anticholinesterase drugs (case history sample) consisted of 84 persons (average age: 75.98, standard deviation = 5.01) with 29.8% men. There were no significant differences with regard to age, sex, basal CAMCOG score or period of time between the two CAMCOG determinations. The averages of the differences between the basal CAMCOG scores and those six months later in the two groups was statistically significant (-1.5275 +/- 7.8458 against -6.7143 +/- 6.1234; p < 0.001). Multivariate analysis of repeat measurements corroborates these findings since significant differences were found between the two groups (p < 0.001) in the results of CAMCOG after six months. Donepezil was seen to be effective in that it delayed cognitive deterioration after six months in patients with minimal and slight degrees of AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
